You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信立泰(002294.SZ):SAL0140藥品臨牀試驗申請獲得受理
格隆匯 02-13 17:31

格隆匯2月13日丨信立泰(002294.SZ)公佈,近日,深圳信立泰藥業股份有限公司收到國家藥品監督管理局核准簽發的受理通知書,公司自主研發的創新小分子藥物SAL0140片(項目代碼:SAL0140)臨牀試驗申請獲得受理。

公司本次提交的申請為SAL0140用於治療未控制高血壓(包括難治性高血壓)的臨牀試驗申請。臨牀前研究顯示,SAL0140選擇性抑制醛固酮合成酶的活性,實現抑制醛固酮的合成而不影響皮質醇的水平。在高血壓猴模型中,SAL0140可顯著抑制醛固酮的生成,每天一次即可達到平穩控制血壓的療效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account